Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Breast cancer
CAR-T cell therapy
Immunosuppressive tumor
Target antigen
Toxicity
Journal
Cellular oncology (Dordrecht)
ISSN: 2211-3436
Titre abrégé: Cell Oncol (Dordr)
Pays: Netherlands
ID NLM: 101552938
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
26
07
2022
pubmed:
10
8
2022
medline:
21
10
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Breast cancer (BC) is a highly prevalent solid cancer with a high-rise infiltration of immune cells, turning it into a significant candidate for tumor-specific immunotherapies. Chimeric antigen receptor (CAR)-T cells are emerging as immunotherapeutic tools with genetically engineered receptors to efficiently recognize and attack tumor cells that express specific target antigens. Technological advancements in CAR design have provided five generations of CAR-T cells applicable to a wide range of cancer patients while boosting CAR-T cell therapy safety. However, CAR-T cell therapy is ineffective against breast cancer because of the loss of specified antigens, the immunosuppressive nature of the tumor and CAR-T cell-induced toxicities. Next-generation CAR-T cells actively pass through the tumor vascular barriers, persist for extended periods and disrupt the tumor microenvironment (TME) to block immune escape. CAR-T cell therapy embodies advanced immunotherapy for BC, but further pre-clinical and clinical assessments are recommended to achieve maximized efficiency and safety.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is a highly prevalent solid cancer with a high-rise infiltration of immune cells, turning it into a significant candidate for tumor-specific immunotherapies. Chimeric antigen receptor (CAR)-T cells are emerging as immunotherapeutic tools with genetically engineered receptors to efficiently recognize and attack tumor cells that express specific target antigens. Technological advancements in CAR design have provided five generations of CAR-T cells applicable to a wide range of cancer patients while boosting CAR-T cell therapy safety. However, CAR-T cell therapy is ineffective against breast cancer because of the loss of specified antigens, the immunosuppressive nature of the tumor and CAR-T cell-induced toxicities. Next-generation CAR-T cells actively pass through the tumor vascular barriers, persist for extended periods and disrupt the tumor microenvironment (TME) to block immune escape.
CONCLUSION
CONCLUSIONS
CAR-T cell therapy embodies advanced immunotherapy for BC, but further pre-clinical and clinical assessments are recommended to achieve maximized efficiency and safety.
Identifiants
pubmed: 35943716
doi: 10.1007/s13402-022-00700-w
pii: 10.1007/s13402-022-00700-w
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-777Informations de copyright
© 2022. Springer Nature Switzerland AG.
Références
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021)
pubmed: 33538338
L.-Y. Yu, J. Tang, C.-M. Zhang, W.-J. Zeng, H. Yan, M.-P. Li et al., New immunotherapy strategies in breast cancer. Int. J. Environ. Res. Public Health 14, 68 (2017)
pmcid: 5295319
A. Bozorgi, S. Khazaei, A. Khademi, M. Khazaei, Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells. Iran J. Basic Med. Sci. 23, 970–983 (2020)
pubmed: 32952942
pmcid: 7478260
V. Seledtsov, A. Goncharov, G. Seledtsova, Multiple-purpose immunotherapy for cancer. Biomed. Pharmacother. 76, 24–29 (2015)
pubmed: 26653546
G. Kroemer, L. Senovilla, L. Galluzzi, F. André, L. Zitvogel, Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128–1138 (2015)
pubmed: 26444637
R. Sommaggio, E. Cappuzzello, A. Dalla Pietà, A. Tosi, P. Palmerini, D. Carpanese et al., Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology 9, 1777046 (2020)
pubmed: 32923140
pmcid: 7458615
L.G. Lum, A. Thakur, Z. Al-Kadhimi, G.A. Colvin, F.J. Cummings, R.D. Legare et al., Targeted T-cell therapy in stage IV breast cancer: A phase I clinical trial. Clin. Cancer Res. 21, 2305–2314 (2015)
pubmed: 25688159
pmcid: 4433762
Q. Li, M. Liu, M. Wu, X. Zhou, S. Wang, Y. Hu et al., PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer. Oncol. Lett. 15, 5924–5932 (2018)
pubmed: 29556312
pmcid: 5844056
A. Janssen, J. Villacorta Hidalgo, D.X. Beringer, S. van Dooremalen, F. Fernando, E. van Diest et al., γδ T-cell receptors derived from breast cancer-infiltrating T lymphocytes mediate antitumor reactivity. Cancer Immunol. Res. 8, 530–543 (2020)
pubmed: 32019779
J.N. Kochenderfer, W.H. Wilson, J.E. Janik, M.E. Dudley, M. Stetler-Stevenson, S.A. Feldman et al., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010)
pubmed: 20668228
pmcid: 2993617
J.N. Kochenderfer, S.A. Rosenberg, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267–276 (2013)
pubmed: 23546520
pmcid: 6322669
D.T. Harris, D.M. Kranz, Adoptive T cell therapies: A comparison of T cell receptors and chimeric antigen receptors. Trends. Pharmacol. Sci. 37, 220–230 (2016)
pubmed: 26705086
B. Heyman, Y. Yang, New developments in immunotherapy for lymphoma. Cancer Biol. Med. 15, 189–209 (2018)
pubmed: 30197788
pmcid: 6121050
R.D. Guest, R.E. Hawkins, N. Kirillova, E.J. Cheadle, J. Arnold, A. O’Neill et al., The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203–211 (2005)
pubmed: 15838376
H. Shi, L. Liu, Z. Wang, Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett. 328, 191–197 (2013)
pubmed: 23022475
Han Y, Xie W, Song D-G, Powell DJ, Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells 11,92. J. Hematol. Oncol. (2018).
X. Meng, R. Jing, L. Qian, C. Zhou, J. Sun, Engineering cytoplasmic signaling of CD28ζ CARs for improved therapeutic functions. Front. Immunol. 11, 1046 (2020)
pubmed: 32636832
pmcid: 7318076
V. Date, S. Nair, Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert. Opin. Biol. Ther. 21, 145–160 (2021)
pubmed: 32882159
A.A. Hombach, H. Abken, Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 129, 2935–2944 (2011)
pubmed: 22030616
P. Li, L. Yang, T. Li, S. Bin, B. Sun, Y. Huang et al., The third generation anti-HER2 chimeric antigen receptor mouse T cells alone or together with anti-PD1 antibody inhibits the growth of mouse breast tumor cells expressing HER2 in vitro and in immune competent mice. Front. Oncol. 10, 1143 (2020)
pubmed: 32766150
pmcid: 7381237
P. Luangwattananun, M. Junking, J. Sujjitjoon, Y. Wutti-In, N. Poungvarin, C. Thuwajit et al., Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Breast Cancer Res. Treat. 186, 25–36 (2021)
pubmed: 33389403
P. Bajgain, S. Tawinwung, L. D’Elia, S. Sukumaran, N. Watanabe, V. Hoyos et al., CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J. Immunother. Cancer 6, 34 (2018)
pubmed: 29747685
pmcid: 5944113
J. Ren, X. Liu, C. Fang, S. Jiang, C.H. June, Y. Zhao, Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin. Cancer Res. 23, 2255–2266 (2017)
pubmed: 27815355
H. Torikai, A. Reik, P.Q. Liu, Y. Zhou, L. Zhang, S. Maiti et al., A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697–5705 (2012)
pubmed: 22535661
pmcid: 3382929
J.H. Cho, J.J. Collins, W.W. Wong, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426-1438.e11 (2018)
pubmed: 29706540
pmcid: 5984158
L.M. Whilding, A.C. Parente-Pereira, T. Zabinski, D.M. Davies, R.M.G. Petrovic, Y.V. Kao et al., Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells. Mol. Ther. 25, 259–273 (2017)
pubmed: 28129120
pmcid: 5261028
K. Bielamowicz, K. Fousek, T.T. Byrd, H. Samaha, M. Mukherjee, N. Aware et al., Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro. Oncol. 20, 506–518 (2018)
pubmed: 29016929
K. Urbanska, E. Lanitis, M. Poussin, R.C. Lynn, B.P. Gavin, S. Kelderman et al., A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844–1852 (2012)
pubmed: 22315351
pmcid: 3319867
Y.G. Lee, I. Marks, M. Srinivasarao, A.K. Kanduluru, S.M. Mahalingam, X. Liu et al., Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 79, 387–396 (2019)
pubmed: 30482775
S. Wilkie, M.C. van Schalkwyk, S. Hobbs, D.M. Davies, S.J. van der Stegen, A.C. Pereira et al., Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059–1070 (2012)
pubmed: 22526592
M. Bajor, A. Graczyk-Jarzynka, K. Marhelava, A. Burdzinska, A. Muchowicz, A. Goral et al., PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J. Immunother. Cancer 10, e002500 (2022)
pubmed: 35078921
pmcid: 8796262
A. Juillerat, A. Marechal, J.M. Filhol, Y. Valogne, J. Valton, A. Duclert et al., An oxygen sensitive self-decision making engineered CAR T-cell. Sci. Rep. 7, 39833 (2017)
pubmed: 28106050
pmcid: 5247770
Y. Cao, D.T. Rodgers, J. Du, I. Ahmad, E.N. Hampton, J.S. Ma et al., Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angew Chem. Int. Ed. Engl. 55, 7520–7524 (2016)
pubmed: 27145250
X. Wang, W.C. Chang, C.W. Wong, D. Colcher, M. Sherman, J.R. Ostberg et al., A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011)
pubmed: 21653320
pmcid: 3152493
M.C. Milone, U. O’Doherty, Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018)
pubmed: 29654266
pmcid: 6035154
M. Poorebrahim, S. Sadeghi, E. Fakhr, M.F. Abazari, V. Poortahmasebi, A. Kheirollahi et al., Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit. Rev. Clin. Lab. Sci. 56, 393–419 (2019)
pubmed: 31314617
L. Xia, Z.Z. Zheng, J.Y. Liu, Y.J. Chen, J.C. Ding, N.S. Xia et al., EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin. Transl. Immunol. 9, e01135 (2020)
A.R. Haas, J.L. Tanyi, M.H. O’Hara, W.L. Gladney, S.F. Lacey, D.A. Torigian et al., Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919–1929 (2019)
pubmed: 31420241
pmcid: 6838875
H. Singh, M.J. Figliola, M.J. Dawson, S. Olivares, L. Zhang, G. Yang et al., Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8, e64138 (2013)
pubmed: 23741305
pmcid: 3669363
V. Lukjanov, I. Koutná, P. Šimara, CAR T-Cell production using nonviral approaches. J. Immunol. Res. 2021, 6644685 (2021)
pubmed: 33855089
pmcid: 8019376
F. Zhou, J. Krishnamurthy, Y. Wei, M. Li, K. Hunt, G.L. Johanning et al., Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. Oncoimmunology 4, e1047582 (2015)
pubmed: 26451325
pmcid: 4589998
K. Nakamura, S. Yagyu, S. Hirota, A. Tomida, M. Kondo, T. Shigeura et al., Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype. Mol. Ther. - Methods Clin. Dev. 21, 315–324 (2021)
pubmed: 33898630
pmcid: 8047430
L.M. Arévalo-Soliz, C.L. Hardee, J.M. Fogg, N.R. Corman, C. Noorbakhsh, L. Zechiedrich, Improving therapeutic potential of non-viral minimized DNA vectors. Cell. Gene Ther. Insights. 6, 1489–1505 (2020)
pubmed: 33953961
pmcid: 8095377
M. Bozza, A.D. Roia, M.P. Correia, A. Berger, A. Tuch, A. Schmidt et al., A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7, eab1333 (2021)
C. Cheng, N. Tang, J. Li, S. Cao, T. Zhang, X. Wei et al., Bacteria-free minicircle DNA system to generate integration-free CAR-T cells. J. Med. Genet. 56, 10–17 (2019)
pubmed: 30030293
A. Bozorgi, M. Khazaei, M. Soleimani, Z. Jamalpoor, Application of nanoparticles in bone tissue engineering; a review on the molecular mechanisms driving osteogenesis. Biomater. Sci. 9, 4541–4567 (2021)
pubmed: 34075945
K.A. Hajj, K.A. Whitehead, Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017)
M.M. Billingsley, N. Singh, P. Ravikumar, R. Zhang, C.H. June, M.J. Mitchell, Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano. Lett. 20, 1578–1589 (2020)
pubmed: 31951421
pmcid: 7313236
Y. Zheng, Z.R. Li, R. Yue, Y.L. Fu, Z.Y. Liu, H.Y. Feng et al., PiggyBac transposon system with polymeric gene carrier transfected into human T cells. Am. J. Transl. Res. 11, 7126–7136 (2019)
pubmed: 31814915
pmcid: 6895516
N.N. Parayath, S.B. Stephan, A.L. Koehne, P.S. Nelson, M.T. Stephan, In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020)
pubmed: 33247092
pmcid: 7695830
P. Sarobe, E. Huarte, J.J. Lasarte, F. Borrás-Cuesta, Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr. Cancer Drug Targets 4, 443–454 (2004)
pubmed: 15320719
J.I. Mori, K. Adachi, Y. Sakoda, T. Sasaki, S. Goto, H. Matsumoto et al., Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Sci. 112, 1417–1428 (2021)
pubmed: 33539630
pmcid: 8019206
R.A. Ghoussoub, D.A. Dillon, T. D’Aquila, E.B. Rimm, E.R. Fearon, D.L. Rimm, Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82, 1513–1520 (1998)
pubmed: 9554529
J. Tchou, Y. Zhao, B.L. Levine, P.J. Zhang, M.M. Davis, J.J. Melenhorst et al., Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol. Res. 5, 1152–1161 (2017)
pubmed: 29109077
pmcid: 5712264
J.A. Krall, E.M. Beyer, G. MacBeath, High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 6, e15945 (2011)
pubmed: 21264347
pmcid: 3018525
G. Bergado Báez, D.R. Hernández Fernández, Z. Mazorra Herrera, R.B. Sánchez, HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. Semin. Oncol. 45, 75–83 (2018)
pubmed: 30318087
Y. Liu, Y. Zhou, K.-H. Huang, Y. Li, X. Fang, L. An et al., EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging 11, 11054–11072 (2019)
pubmed: 31804974
pmcid: 6932924
L. Xia, Z. Zheng, J.Y. Liu, Y.J. Chen, J. Ding, G.S. Hu et al., Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol. Res. 9, 707–722 (2021)
pubmed: 33875483
C. Jackisch, P. Lammers, I. Jacobs, Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast 32, 199–216 (2017)
pubmed: 28236776
Á. Szöőr, G. Tóth, B. Zsebik, V. Szabó, Z. Eshhar, H. Abken et al., Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484, 1–8 (2020)
pubmed: 32289441
H. Li, W. Yuan, S. Bin, G. Wu, P. Li, M. Liu et al., Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. Am. J. Cancer Res. 10, 688–703 (2020)
pubmed: 32195036
pmcid: 7061754
G. Tozbikian, E. Brogi, K. Kadota, J. Catalano, M. Akram, S. Patil et al., Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE 9, e114900 (2014)
pubmed: 25506917
pmcid: 4266616
J. Tchou, L.-C. Wang, B. Selven, H. Zhang, J. Conejo-Garcia, H. Borghaei et al., Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res. Treat. 133, 799–804 (2012)
pubmed: 22418702
pmcid: 4964602
R. Hassan, A. Thomas, C. Alewine, D.T. Le, E.M. Jaffee, I. Pastan, Mesothelin immunotherapy for cancer: ready for prime time? J. Clin. Oncol. 34, 4171–4179 (2016)
pubmed: 27863199
pmcid: 5477819
Z. Tang, M. Qian, M. Ho, The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med. Chem. 13, 276–280 (2013)
pubmed: 22721387
pmcid: 3568227
Y. Li, F. Xiao, A. Zhang, D. Zhang, W. Nie, T. Xu et al., Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol. 348, 104041 (2020)
pubmed: 31983398
Z. Zhang, D. Jiang, H. Yang, Z. He, X. Liu, W. Qin et al., Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 10, 476 (2019)
pubmed: 31209210
pmcid: 6572851
M. Jäger, A. Schoberth, P. Ruf, J. Hess, M. Hennig, B. Schmalfeldt et al., Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM× anti-CD3). Cancer Res. 72, 24–32 (2012)
pubmed: 22044753
A. Martowicz, G. Spizzo, G. Gastl, G. Untergasser, Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12, 501 (2012)
pubmed: 23110550
pmcid: 3519683
M. Kubo, M. Umebayashi, K. Kurata, H. Mori, M. Kai, H. Onishi et al., Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines. Anticancer Res. 38, 4273–4279 (2018)
pubmed: 29970561
Q. Zhang, H. Zhang, J. Ding, H. Liu, H. Li, H. Li et al., Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. J. Immunol. Res. 2018, 4263520 (2018)
pubmed: 30410941
pmcid: 6205314
J. Fu, Y. Shang, Z. Qian, J. Hou, F. Yan, G. Liu et al., Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model. J. Vet. Med. Sci. 83, 241–247 (2021)
pubmed: 33328392
D. Qin, D. Li, B. Zhang, Y. Chen, X. Liao, X. Li et al., Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology 9, 1806009 (2020)
pubmed: 32923168
pmcid: 7458607
K. Lund, J.L. Dembinski, N. Solberg, A. Urbanucci, I.G. Mills, S. Krauss, Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLoS One 10, e0123684 (2015)
pubmed: 25860483
pmcid: 4393253
K. Doberstein, K. Milde-Langosch, N.P. Bretz, U. Schirmer, A. Harari, I. Witzel et al., L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC Cancer 14, 958 (2014)
pubmed: 25510351
pmcid: 4301892
J. Zhang, F. Yang, Y. Ding, L. Zhen, X. Han, F. Jiao et al., Overexpression of L1 cell adhesion molecule correlates with aggressive tumor progression of patients with breast cancer and promotes motility of breast cancer cells. Int. J. Clin. Exp. Pathol. 8, 9240–9247 (2015)
pubmed: 26464672
pmcid: 4583904
H. Zhang, C.C. Wong, H. Wei, D.M. Gilkes, P. Korangath, P. Chaturvedi et al., HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31, 1757–1770 (2012)
pubmed: 21860410
X. Wu, Z. Yin, C. McKay, C. Pett, J. Yu, M. Schorlemer et al., Protective epitope discovery and design of MUC1-based vaccine for effective tumor protections in immunotolerant mice. J. Am. Chem. Soci. 140, 16596–16609 (2018)
R. Zhou, M. Yazdanifar, L.D. Roy, L.M. Whilding, A. Gavrill, J. Maher et al., CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front. Immunol. 10, 1149 (2019)
pubmed: 31178870
pmcid: 6543840
M. Antonilli, H. Rahimi, V. Visconti, C. Napoletano, I. Ruscito, I.G. Zizzari et al., Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. Int. J. Oncol. 48, 1369–1378 (2016)
pubmed: 26892612
pmcid: 4777599
R. Bei, J. Kantor, S.V. Kashmiri, S. Abrams, J. Schlom, Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J. Immunother. Emphasis Tumor Immunol. 16, 275–282 (1994)
pubmed: 7881636
S.E. Cha, M. Kujawski, J.P. Yazaki, C. Brown, J.E. Shively, Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 10, 1899469 (2021)
pubmed: 33796409
pmcid: 7993151
M. Loeffler, J.A. Krüger, A.G. Niethammer, R.A. Reisfeld, Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116, 1955–1962 (2006)
pubmed: 16794736
pmcid: 1481657
M. Meng, W. Wang, J. Yan, J. Tan, L. Liao, J. Shi et al., Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model. Tumour Biol. 37, 10317–10327 (2016)
pubmed: 26842926
S. Zhang, L. Chen, B. Cui, H.Y. Chuang, J. Yu, J. Wang-Rodriguez et al., ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7, e31127 (2012)
pubmed: 22403610
pmcid: 3293865
A. Kamrani, A. Mehdizadeh, M. Ahmadi, L. Aghebati-Maleki, M. Yousefi, Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert. Opin. Ther. Targets 23, 447–456 (2019)
pubmed: 30935250
L. Wallstabe, C. Göttlich, L.C. Nelke, J. Kühnemundt, T. Schwarz, T. Nerreter et al., ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight 4, e126345 (2019)
pmcid: 6795380
S. Srivastava, A.I. Salter, D. Liggitt, S. Yechan-Gunja, M. Sarvothama, K. Cooper et al., Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503 (2019)
pubmed: 30889382
pmcid: 6450658
R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, S.A. Rosenberg, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010)
pubmed: 20179677
pmcid: 2862534
K.T. Roybal, L.J. Rupp, L. Morsut, W.J. Walker, K.A. McNally, J.S. Park et al., Precision tumor recognition by T cells with combinatorial antigen-sensing Circuits. Cell 164, 770–779 (2016)
pubmed: 26830879
pmcid: 4752902
X. Han, P.D. Bryson, Y. Zhao, G.E. Cinay, S. Li, Y. Guo et al., Masked chimeric antigen receptor for tumor-specific activation. Mol. Ther. 25, 274–284 (2017)
pubmed: 28129121
pmcid: 5363190
L. Nagl, L. Horvath, A. Pircher, D. Wolf, Tumor endothelial cells (TECs) as potential immune directors of the tumor microenvironment - new findings and future perspectives. Front. Cell. Dev. Biol. 8, 766 (2020)
pubmed: 32974337
pmcid: 7466447
D. Klein, The tumor vascular endothelium as decision maker in cancer therapy. Front. Oncol. 8, 367 (2018)
pubmed: 30250827
pmcid: 6139307
D. Lambrechts, E. Wauters, B. Boeckx, S. Aibar, D. Nittner, O. Burton et al., Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018)
pubmed: 29988129
T.H. Nasti, D.C. Bullard, N. Yusuf, P-selectin enhances growth and metastasis of mouse mammary tumors by promoting regulatory T cell infiltration into the tumors. Life Sci. 131, 11–18 (2015)
pubmed: 25865803
G.T. Motz, S.P. Santoro, L.-P. Wang, T. Garrabrant, R.R. Lastra, I.S. Hagemann et al., Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607–615 (2014)
pubmed: 24793239
pmcid: 4060245
Y. Jiang, Y. Li, B. Zhu, T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015)
pubmed: 26086965
pmcid: 4669840
Y. Liu, G. Liu, J. Wang, Z.-y Zheng, L. Jia, W. Rui et al., Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med 13, eabb5191 (2021)
pubmed: 33762437
M. Hamieh, A. Dobrin, A. Cabriolu, S.J.C. van der Stegen, T. Giavridis, J. Mansilla-Soto et al., CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–116 (2019)
pubmed: 30918399
pmcid: 6707377
M. Castellarin, K. Watanabe, C.H. June, C.C. Kloss, A.D. Posey Jr., Driving cars to the clinic for solid tumors. Gene Ther. 25, 165–175 (2018)
pubmed: 29880908
E. Mamessier, A. Sylvain, M.-L. Thibult, G. Houvenaeghel, J. Jacquemier, R. Castellano et al., Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609–3622 (2011)
pubmed: 21841316
pmcid: 3171102
C. Gómez-Aleza, B. Nguyen, G. Yoldi, M. Ciscar, A. Barranco, E. Hernández-Jiménez et al., Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nat. Commun. 11, 6335 (2020)
pubmed: 33303745
pmcid: 7728758
L.A. Moraes, S. Kar, S.L. Foo, T. Gu, Y.Q. Toh, P.B. Ampomah et al., Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment. Sci. Rep. 7, 17925 (2017)
pubmed: 29263330
pmcid: 5738423
R. Wang, Y. Liu, L. Liu, M. Chen, X. Wang, J. Yang et al., Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. EBioMedicine 40, 118–134 (2019)
pubmed: 30711520
pmcid: 6413476
Z.F. Wen, H. Liu, R. Gao, M. Zhou, J. Ma, Y. Zhang et al., Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J. Immunother. Cancer 6, 151 (2018)
pubmed: 30563569
pmcid: 6299637
C. Liu, J. Qiang, Q. Deng, J. Xia, L. Deng, L. Zhou et al., ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 81, 5919–5934 (2021)
pubmed: 34580061
B. Yu, F. Luo, B. Sun, W. Liu, Q. Shi, S.Y. Cheng et al., KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer. Adv Sci (Weinh) 8, e2100014 (2021)
A. Volpe, C. Lang, L. Lim, F. Man, E. Kurtys, C. Ashmore-Harris et al., Spatiotemporal PET imaging rveals differences in CAR-T tumor retention in triple-negative breast cancer models. Mol. Ther. 28, 2271–2285 (2020)
pubmed: 32645298
pmcid: 7544977
L. Cassetta, S. Fragkogianni, A.H. Sims, A. Swierczak, L.M. Forrester, H. Zhang et al., Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic Targets. Cancer Cell 35, 588-602.e10 (2019)
pubmed: 30930117
pmcid: 6472943
A.A. Barkal, R.E. Brewer, M. Markovic, M. Kowarsky, S.A. Barkal, B.W. Zaro et al., CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019)
pubmed: 31367043
pmcid: 6697206
A.K. Mehta, S. Kadel, M.G. Townsend, M. Oliwa, J.L. Guerriero, Macrophage biology and mechanisms of immune suppression in breast cancer. Front. Immunol. 12, 643771 (2021)
pubmed: 33968034
pmcid: 8102870
S. Su, J. Liao, J. Liu, D. Huang, C. He, F. Chen et al., Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer. Cell Res. 27, 461–482 (2017)
pubmed: 28290464
pmcid: 5385617
S.A. Nalawade, P. Shafer, P. Bajgain, M.K. McKenna, A. Ali, L. Kelly et al., Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J. Immunother. Cancer 9, e003237 (2021)
pubmed: 34815355
pmcid: 8611441
L. Speigl, H. Burow, J.K. Bailur, N. Janssen, C.B. Walter, G. Pawelec et al., CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. Breast Cancer Res. Treat. 168, 401–411 (2018)
pubmed: 29230664
Z. Fang, C. Wen, X. Chen, R. Yin, C. Zhang, X. Wang et al., Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. Oncotarget 8, 54173–54186 (2017)
pubmed: 28903332
pmcid: 5589571
J. Yu, W. Du, F. Yan, Y. Wang, H. Li, S. Cao et al., Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190, 3783–3797 (2013)
pubmed: 23440412
Y. Sharon, Y. Raz, N. Cohen, A. Ben-Shmuel, H. Schwartz, T. Geiger et al., Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res. 75, 963–973 (2015)
pubmed: 25600648
S. Baroni, S. Romero-Cordoba, I. Plantamura, M. Dugo, E. D’Ippolito, A. Cataldo et al., Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis. 7, e2312 (2016)
pubmed: 27468688
pmcid: 4973361
A. Li, P. Chen, Y. Leng, J. Kang, Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. Oncogene 37, 5952–5966 (2018)
pubmed: 29980788
N. Cohen, O. Shani, Y. Raz, Y. Sharon, D. Hoffman, L. Abramovitz et al., Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 36, 4457–4468 (2017)
pubmed: 28368410
pmcid: 5507301
A. Costa, Y. Kieffer, A. Scholer-Dahirel, F. Pelon, B. Bourachot, M. Cardon et al., Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463-479.e10 (2018)
pubmed: 29455927
Y. Kieffer, H.R. Hocine, G. Gentric, F. Pelon, C. Bernard, B. Bourachot et al., Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330–1351 (2020)
pubmed: 32434947
G. Hu, P. Cheng, J. Pan, S. Wang, Q. Ding, Z. Jiang et al., An IL6-adenosine positive feedback loop between CD73(+) γδTregs and CAFs promotes tumor progression in human breast cancer. Cancer Immunol. Res. 8, 1273–1286 (2020)
pubmed: 32847938
R. Allaoui, C. Bergenfelz, S. Mohlin, C. Hagerling, K. Salari, Z. Werb et al., Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat. Commun. 7, 13050 (2016)
pubmed: 27725631
pmcid: 5062608
S. Khazaei, G. Keshavarz, A. Bozorgi, H. Nazari, M. Khazaei, Adipose tissue-derived stem cells: a comparative review on isolation, culture, and differentiation methods. Cell Tissue Bank 23, 1–16 (2021)
pubmed: 33616792
S. Aravindhan, S.S. Ejam, M.H. Lafta, A. Markov, A.V. Yumashev, M. Ahmadi, Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature. Cancer Cell Int. 21, 158 (2021)
pubmed: 33685452
pmcid: 7938588
M.E. Castro-Manrreza, Participation of mesenchymal stem cells in the regulation of immune response and cancer development. Bol. Med. Hosp. Infant Mex. 73, 380–387 (2016)
pubmed: 29421282
S. Biswas, G. Mandal, S. Roy Chowdhury, S. Purohit, K.K. Payne, C. Anadon et al., Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer. J. Immunol. 203, 3447–3460 (2019)
pubmed: 31704881
H. Aboulkheyr Es, B. Bigdeli, S. Zhand, A.R. Aref, J.P. Thiery, M.E. Warkiani, Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells. J. Cell Physiol. 236, 3918–3928 (2021)
pubmed: 33145762
M. Razmkhah, M. Jaberipour, N. Erfani, M. Habibagahi, A.R. Talei, A. Ghaderi, Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Cell Immunol. 266, 116–122 (2011)
pubmed: 20970781
M. Egeblad, M.G. Rasch, V.M. Weaver, Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 22, 697–706 (2010)
pubmed: 20822891
pmcid: 2948601
D.E. Kuczek, A.M.H. Larsen, M.L. Thorseth, M. Carretta, A. Kalvisa, M.S. Siersbæk et al., Collagen density regulates the activity of tumor-infiltrating T cells. J. Immunother. Cancer 7, 68 (2019)
pubmed: 30867051
pmcid: 6417085
K. Esbona, D. Inman, S. Saha, J. Jeffery, P. Schedin, L. Wilke et al., COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 18, 35 (2016)
pubmed: 27000374
pmcid: 4802888
A.M.H. Larsen, D.E. Kuczek, A. Kalvisa, M.S. Siersbæk, M.L. Thorseth, A.Z. Johansen et al., Collagen density modulates the immunosuppressive functions of macrophages. J. Immunol. 205, 1461–1472 (2020)
pubmed: 32839214
C. Robertson, A. Sebastian, A. Hinckley, N.D. Rios-Arce, W.F. Hynes, S.A. Edwards et al., Extracellular matrix modulates T cell clearance of malignant cells in vitro. Biomaterials 282, 121378 (2022)
pubmed: 35121359
K.S. Midwood, M. Chiquet, R.P. Tucker, G. Orend, Tenascin-C at a glance. J. Cell Sci. 129, 4321–4327 (2016)
pubmed: 27875272
R. Chiquet-Ehrismann, M. Chiquet, Tenascins: regulation and putative functions during pathological stress. J. Pathol. 200, 488–499 (2003)
pubmed: 12845616
C. Deligne, D. Murdamoothoo, A.N. Gammage, M. Gschwandtner, W. Erne, T. Loustau et al., Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype. Cancer Immunol. Res. 8, 368–382 (2020)
pubmed: 31941671
pmcid: 7611136
D. Murdamoothoo, Z. Sun, A. Yilmaz, G. Riegel, C. Abou-Faycal, C. Deligne et al., Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression. EMBO Mol. Med. 13, e13270 (2021)
pubmed: 33988305
pmcid: 8185552
Z.L. Li, H.L. Zhang, Y. Huang, J.H. Huang, P. Sun, N.N. Zhou et al., Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat. Commun. 11, 3806 (2020)
pubmed: 32732922
pmcid: 7393512
J. Cen, L. Feng, H. Ke, L. Bao, L.Z. Li, Y. Tanaka et al., Exosomal thrombospondin-1 disrupts the integrity of endothelial intercellular junctions to facilitate breast cancer cell metastasis. Cancers (Basel). 11, 1946 (2019)
pmcid: 6966578
T.W. Miller, S. Kaur, K. Ivins-O’Keefe, D.D. Roberts, Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 32, 316–324 (2013)
pubmed: 23499828
pmcid: 3706541
P.P. Manna, W.A. Frazier, The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J. Immunol. 170, 3544–3553 (2003)
pubmed: 12646616
P. Grimbert, S. Bouguermouh, N. Baba, T. Nakajima, Z. Allakhverdi, D. Braun et al., Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J. Immunol. 177, 3534–3541 (2006)
pubmed: 16951312
F.A. Mir, L. Contreras-Ruiz, S. Masli, Thrombospondin-1-dependent immune regulation by transforming growth factor-β2-exposed antigen-presenting cells. Immunology 146, 547–556 (2015)
pubmed: 26458493
pmcid: 4693892
T. Triulzi, P. Casalini, M. Sandri, M. Ratti, M.L. Carcangiu, M.P. Colombo et al., Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 8, e56761 (2013)
pubmed: 23441215
pmcid: 3575489
S. Sangaletti, C. Tripodo, A. Santangelo, N. Castioni, P. Portararo, A. Gulino et al., Mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity. Cell Rep. 17, 233–248 (2016)
pubmed: 27681434
S. Sangaletti, L. Gioiosa, C. Guiducci, G. Rotta, M. Rescigno, A. Stoppacciaro et al., Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J. Cell Sci. 118, 3685–3694 (2005)
pubmed: 16046482
A. Papadas, G. Arauz, A. Cicala, J. Wiesner, F. Asimakopoulos, Versican and versican-matrikines in cancer progression, inflammation, and immunity. J. Histochem. Cytochem. 68, 871–885 (2020)
pubmed: 32623942
pmcid: 7711242
S.P. Evanko, S. Potter-Perigo, P.L. Bollyky, G.T. Nepom, T.N. Wight, Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 31, 90–100 (2012)
pubmed: 22155153
D.C. Dos Reis, K.A. Damasceno, C.B. de Campos, E.S. Veloso, G.R.A. Pêgas, L.R. Kraemer et al., Versican and tumor-associated macrophages promotes tumor progression and metastasis in canine and murine models of breast carcinoma. Front. Oncol. 9, 577 (2019)
pubmed: 31334111
pmcid: 6616078
M. Tang, J. Diao, M.S. Cattral, Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cell Mol. Life Sci. 74, 761–776 (2017)
pubmed: 27491428
V.W. Xue, J.Y.-F. Chung, C.A.G. Córdoba, A.H.-K. Cheung, W. Kang, E.W.F. Lam et al., Transforming growth factor-β: A multifunctional regulator of cancer immunity. Cancers 12, 3099 (2020)
pmcid: 7690808
T. Stüber, R. Monjezi, L. Wallstabe, J. Kühnemundt, S.L. Nietzer, G. Dandekar et al., Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer 8, e000676 (2020)
pubmed: 32303620
pmcid: 7204619
B. Guo, S. Fu, J. Zhang, B. Liu, Z. Li, Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep 6, 36107 (2016)
pubmed: 27786298
pmcid: 5082376
S. Tu, G. Bhagat, G. Cui, S. Takaishi, E.A. Kurt-Jones, B. Rickman et al., Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408–419 (2008)
pubmed: 18977329
pmcid: 2586894
I. Kaplanov, Y. Carmi, R. Kornetsky, A. Shemesh, G.V. Shurin, M.R. Shurin et al., Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl. Acad. Sci. U. S A. 116, 1361–1369 (2019)
pubmed: 30545915
C. Voigt, P. May, A. Gottschlich, A. Markota, D. Wenk, I. Gerlach et al., Cancer cells induce interleukin-22 production from memory CD4(+) T cells via interleukin-1 to promote tumor growth. Proc. Natl. Acad. Sci. U. S. A. 114, 12994–12999 (2017)
pubmed: 29150554
pmcid: 5724250
E. Sheikhpour, P. Noorbakhsh, E. Foroughi, S. Farahnak, R. Nasiri, H. Neamatzadeh, A survey on the role of interleukin-10 in breast cancer: A narrative. Rep. Biochem. Mol. Biol. 7, 30–37 (2018)
pubmed: 30324115
pmcid: 6175593
M. El-Nadi, H. Hassan, M.E. Saleh, E. Nassar, Y.M. Ismail, M. Amer et al., Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas. Matrix Biol. Plus. 6–7, 100030 (2020)
pubmed: 33543027
pmcid: 7852308
Malefyt R. de Waal, H. Yssel, J.E. de Vries, Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells Specific inhibition of IL-2 production and proliferation. J. Immunol. 150, 4754–65 (1993)
A. Chaudhry, R.M. Samstein, P. Treuting, Y. Liang, M.C. Pils, J.M. Heinrich et al., Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34, 566–578 (2011)
pubmed: 21511185
pmcid: 3088485
I.H. Park, H.N. Yang, K.J. Lee, T.S. Kim, E.S. Lee, S.Y. Jung et al., Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget 8, 32722–32730 (2017)
pubmed: 28415798
pmcid: 5464822
S. Hao, X. Chen, F. Wang, Q. Shao, J. Liu, H. Zhao et al., Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. Carcinogenesis 39, 1488–1496 (2018)
pubmed: 30321288
M. Damo, N.S. Joshi, T(reg) cell IL-10 and IL-35 exhaust CD8(+) T cells in tumors. Nat. Immunol. 20, 674–675 (2019)
pubmed: 31011189
H. Jiang, T. Zhang, M.-X. Yan, W. Wu, IL-35 inhibits CD8 + T cells activity by suppressing expression of costimulatory molecule CD28 and Th1 cytokine production. Transl. Cancer Res. 8, 1319–1325 (2019)
pubmed: 35116874
pmcid: 8797787
Q.Q. Ding, J.M. Chauvin, H.M. Zarour, Targeting novel inhibitory receptors in cancer immunotherapy. Semin. Immunol. 49, 101436 (2020)
pubmed: 33288379
pmcid: 8045408
B.A. Pockaj, G.D. Basu, L.B. Pathangey, R.J. Gray, J.L. Hernandez, S.J. Gendler et al., Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 11, 328–339 (2004)
pubmed: 14993030
J. Sun, J. Yu, H. Li, L. Yang, F. Wei, W. Yu et al., Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J. Exp. Clin. Cancer Res. 30, 82 (2011)
pubmed: 21917155
pmcid: 3184069
E.A. Dill, P.M. Dillon, T.N. Bullock, A.M. Mills, IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod. Pathol. 31, 1513–1522 (2018)
pubmed: 29802358
J.D. Mezrich, J.H. Fechner, X. Zhang, B.P. Johnson, W.J. Burlingham, C.A. Bradfield, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010)
pubmed: 20720200
F. Fallarino, U. Grohmann, C. Vacca, R. Bianchi, C. Orabona, A. Spreca et al., T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069–1077 (2002)
pubmed: 12232795
B. Heng, A.A. Bilgin, D.B. Lovejoy, V.X. Tan, H.H. Milioli, L. Gluch et al., Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression. Breast Cancer Res. 22, 113 (2020)
pubmed: 33109232
pmcid: 7590459
A.N. Macintyre, V.A. Gerriets, A.G. Nichols, R.D. Michalek, M.C. Rudolph, D. Deoliveira et al., The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61–72 (2014)
pubmed: 24930970
pmcid: 4079750
W. Li, T. Tanikawa, I. Kryczek, H. Xia, G. Li, K. Wu et al., Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 28, 87-103.e6 (2018)
pubmed: 29805099
pmcid: 6238219
A. Schurich, I. Magalhaes, J. Mattsson, Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. Immunotherapy 11, 335–345 (2019)
pubmed: 30678555
G. Multhoff, P. Vaupel, Hypoxia compromises anti-cancer immune responses. Adv. Exp. Med. Biol. 1232, 131–143 (2020)
pubmed: 31893404
K. Sek, L.M. Kats, P.K. Darcy, P.A. Beavis, Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. Curr. Opin. Pharmacol. 53, 91–97 (2020)
pubmed: 32854024
D. Jin, J. Fan, L. Wang, L.F. Thompson, A. Liu, B.J. Daniel et al., CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245–2255 (2010)
pubmed: 20179192
pmcid: 2883609
V. Huber, C. Camisaschi, A. Berzi, S. Ferro, L. Lugini, T. Triulzi et al., Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin. Cancer Biol. 43, 74–89 (2017)
pubmed: 28267587
K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger et al., Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819 (2007)
pubmed: 17255361
M. Bosticardo, S. Ariotti, G. Losana, P. Bernabei, G. Forni, F. Novelli, Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation. Eur. J. Immunol. 31, 2829–2838 (2001)
pubmed: 11536182
Y. Wang, K.F. Goliwas, P.E. Severino, K.P. Hough, D. Van Vessem, H. Wang et al., Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. Lab. Invest. 100, 1503–1516 (2020)
pubmed: 32572176
pmcid: 7686122
B. Aykut, R. Chen, J.I. Kim, D. Wu, S.A.A. Shadaloey, R. Abengozar et al., Targeting Piezo1 unleashes innate immunity against cancer and infectious disease. Sci Immunol 5, eabb5168 (2020)
pubmed: 32826342
S. Park, Y. Shi, B.C. Kim, M.H. Jo, L.O. Cruz, Z. Gou et al., Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation. Biosens Bioelectron. 165, 112389 (2020)
pubmed: 32729511
pmcid: 8011575
S.C. Howard, D.P. Jones, C.H. Pui, The tumor lysis syndrome. N Engl. J. Med. 364, 1844–1854 (2011)
pubmed: 21561350
pmcid: 3437249
K.A. Hay, L.A. Hanafi, D. Li, J. Gust, W.C. Liles, M.M. Wurfel et al., Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295–2306 (2017)
pubmed: 28924019
pmcid: 5701525
J.N. Brudno, J.N. Kochenderfer, Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 34, 45–55 (2019)
pubmed: 30528964
M. Hudecek, M.T. Lupo-Stanghellini, P.L. Kosasih, D. Sommermeyer, M.C. Jensen, C. Rader et al., Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164 (2013)
pubmed: 23620405
pmcid: 3804130
N. Xu, D.C. Palmer, A.C. Robeson, P. Shou, H. Bommiasamy, S.J. Laurie et al., STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J. Exp Med. 218, e20200844 (2021)
pubmed: 33382402
P.S. Adusumilli, L. Cherkassky, J. Villena-Vargas, C. Colovos, E. Servais, J. Plotkin et al., Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014)
pubmed: 25378643
pmcid: 4373413
C.E. Brown, B. Aguilar, R. Starr, X. Yang, W.C. Chang, L. Weng et al., Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol. Ther. 26, 31–44 (2018)
pubmed: 29103912
A. Klampatsa, V. Dimou, S.M. Albelda, Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert. Opin. Biol. Ther. 21, 473–486 (2020)
pubmed: 33176519
S. Yu, M. Yi, S. Qin, K. Wu, Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol. Cancer 18, 125 (2019)
pubmed: 31429760
pmcid: 6701025
T. Soundara Rajan, A. Gugliandolo, P. Bramanti, E. Mazzon, In vitro-transcribed mRNA chimeric antigen receptor T cell (IVT mRNA CAR T) therapy in hematologic and solid tumor management: A preclinical update. Int. J. Mol. Sci. 21, 6514 (2020)
pmcid: 7556036
A. Ager, High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front. Immunol. 8, 45 (2017)
pubmed: 28217126
pmcid: 5289948
M. Martinez, E.K. Moon, CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019)
pubmed: 30804938
pmcid: 6370640
Y. Zhang, X. Xie, P.N. Yeganeh, D.J. Lee, D. Valle-Garcia, K.F. Meza-Sosa et al., Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proc. Natl. Acad. Sci. U. S. A. 118, e2022830118 (2021)
pubmed: 33627408
pmcid: 7936362
L. Cherkassky, A. Morello, J. Villena-Vargas, Y. Feng, D.S. Dimitrov, D.R. Jones et al., Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016)
pubmed: 27454297
pmcid: 4966328
R. Sun, H. Luo, J. Su, S. Di, M. Zhou, B. Shi et al., Olaparib suppresses MDSC recruitment via SDF1α/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol. Ther. 29, 60–74 (2021)
pubmed: 33010818
Y. Zou, B. Liu, L. Li, Q. Yin, J. Tang, Z. Jing et al., IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. Cancer Lett. 524, 121–130 (2022)
pubmed: 34687790
G. Tóth, J. Szöllősi, H. Abken, G. Vereb, Á. Szöőr, A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts. Int. J. Mol. Sci. 21, 1039 (2020)
pmcid: 7038081